Breaking News

Friday
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Periodicals
J&J director says company could boost vaccine availability by spring, CNBC says » 16:18
01/22/21
01/22
16:18
01/22/21
16:18
JNJ

Johnson & Johnson

$163.68 /

+1.99 (+1.23%)

Johnson & Johnson…

Johnson & Johnson board member Dr. Mark McClellan said that "if the clinical trial works out," the company may be able to significantly boost America's COVID-19 vaccine supply availability within a matter of weeks, CNBC's Emily DeCiccio reports. I do know that J&J is making a very large supply, going all out with its production, both here in the U.S. and elsewhere around the world, with the goal of having perhaps enough vaccines for 100 million Americans by spring, by this April or so," said the former FDA Commissioner in a Thursday evening interview on CNBC. Reference Link

ShowHide Related Items >><<
JNJ Johnson & Johnson
$163.68 /

+1.99 (+1.23%)

JNJ Johnson & Johnson
$163.68 /

+1.99 (+1.23%)

01/15/21 B. Riley Securities
Arcturus Therapeutics downgraded to Neutral from Buy at B. Riley Securities
01/14/21 Morgan Stanley
80%+ efficacy from J&J vaccine would be 'compelling,' says Morgan Stanley
01/14/21 Oppenheimer
Essa Pharma price target raised to $20 from $9 at Oppenheimer
12/29/20 Piper Sandler
Piper still believes in Arcturus vaccine after 'underwhelming' immunogenicity
JNJ Johnson & Johnson
$163.68 /

+1.99 (+1.23%)

JNJ Johnson & Johnson
$163.68 /

+1.99 (+1.23%)

JNJ Johnson & Johnson
$163.68 /

+1.99 (+1.23%)

JNJ Johnson & Johnson
$163.68 /

+1.99 (+1.23%)

Recommendations
Intuitive Surgical price target raised to $840 from $825 at JPMorgan » 09:55
01/22/21
01/22
09:55
01/22/21
09:55
ISRG

Intuitive Surgical

/

+

JPMorgan analyst Tycho…

JPMorgan analyst Tycho Peterson raised the firm's price target on Intuitive Surgical to $840 from $825 and reiterates an Overweight rating on the shares following last night's "solid" results. The quarter showcased a "measured recovery," and the rollout of flexible financing programs, combined with disciplined investments, are "smart moves to grow the competitive moat ahead of new entrants," Peterson tells investors in a research note. The analyst continues to see longer-term catalysts to drive upside, including the China quota, unpenetrated procedures, SP ramp and Ion commercial ramp.

ShowHide Related Items >><<
ISRG Intuitive Surgical
/

+

ISRG Intuitive Surgical
/

+

01/22/21 Raymond James
Intuitive Surgical price target raised to $865 from $800 at Raymond James
01/22/21 Wells Fargo
Intuitive Surgical price target raised to $879 from $841 at Wells Fargo
01/22/21 Oppenheimer
Intuitive Surgical price target raised to $410 from $365 at Oppenheimer
01/22/21 Piper Sandler
Intuitive Surgical price target raised to $730 from $680 at Piper Sandler
ISRG Intuitive Surgical
/

+

ISRG Intuitive Surgical
/

+

ISRG Intuitive Surgical
/

+

Recommendations
Intuitive Surgical price target raised to $865 from $800 at Raymond James » 09:20
01/22/21
01/22
09:20
01/22/21
09:20
ISRG

Intuitive Surgical

$799.43 /

-0.18 (-0.02%)

Raymond James analyst…

Raymond James analyst Lawrence Keusch raised the firm's price target on Intuitive Surgical to $865 from $800 and keeps an Outperform rating on the shares following the company's "solid" Q4 results. Looking into 2021, Keusch says there remains COVID-related uncertainty and he expects Q1 to be the most significantly impacted period of the year.

ShowHide Related Items >><<
ISRG Intuitive Surgical
$799.43 /

-0.18 (-0.02%)

ISRG Intuitive Surgical
$799.43 /

-0.18 (-0.02%)

01/22/21 Wells Fargo
Intuitive Surgical price target raised to $879 from $841 at Wells Fargo
01/22/21 Oppenheimer
Intuitive Surgical price target raised to $410 from $365 at Oppenheimer
01/22/21 Piper Sandler
Intuitive Surgical price target raised to $730 from $680 at Piper Sandler
12/15/20 Morgan Stanley
Intuitive Surgical downgraded to Equal Weight on valuation at Morgan Stanley
ISRG Intuitive Surgical
$799.43 /

-0.18 (-0.02%)

ISRG Intuitive Surgical
$799.43 /

-0.18 (-0.02%)

ISRG Intuitive Surgical
$799.43 /

-0.18 (-0.02%)

Recommendations
Intuitive Surgical price target raised to $879 from $841 at Wells Fargo » 07:02
01/22/21
01/22
07:02
01/22/21
07:02
ISRG

Intuitive Surgical

$799.43 /

-0.18 (-0.02%)

Wells Fargo analyst…

Wells Fargo analyst Lawrence Biegelsen raised the firm's price target on Intuitive Surgical to $879 from $841 and keeps an Overweight rating on the shares. The company's Q4 results were driven by better-than-expected da Vinci shipments and higher stocking orders as a result of the Extended Use program, Biegelsen tells investors in a research note.

ShowHide Related Items >><<
ISRG Intuitive Surgical
$799.43 /

-0.18 (-0.02%)

ISRG Intuitive Surgical
$799.43 /

-0.18 (-0.02%)

01/22/21 Oppenheimer
Intuitive Surgical price target raised to $410 from $365 at Oppenheimer
01/22/21 Piper Sandler
Intuitive Surgical price target raised to $730 from $680 at Piper Sandler
12/15/20 Morgan Stanley
Intuitive Surgical downgraded to Equal Weight on valuation at Morgan Stanley
12/15/20 Morgan Stanley
Intuitive Surgical downgraded to Equal Weight from Overweight at Morgan Stanley
ISRG Intuitive Surgical
$799.43 /

-0.18 (-0.02%)

ISRG Intuitive Surgical
$799.43 /

-0.18 (-0.02%)

ISRG Intuitive Surgical
$799.43 /

-0.18 (-0.02%)

Recommendations
Intuitive Surgical price target raised to $410 from $365 at Oppenheimer » 06:29
01/22/21
01/22
06:29
01/22/21
06:29
ISRG

Intuitive Surgical

$799.43 /

-0.18 (-0.02%)

Oppenheimer analyst Suraj…

Oppenheimer analyst Suraj Kalia raised the firm's price target on Intuitive Surgical to $410 from $365 and keeps an Underperform rating on the shares following its Q4 earnings report. Kalia believes the fundamentals remain challenged despite a valuation that seems overly optimistic.

ShowHide Related Items >><<
ISRG Intuitive Surgical
$799.43 /

-0.18 (-0.02%)

ISRG Intuitive Surgical
$799.43 /

-0.18 (-0.02%)

01/22/21 Piper Sandler
Intuitive Surgical price target raised to $730 from $680 at Piper Sandler
12/15/20 Morgan Stanley
Intuitive Surgical downgraded to Equal Weight on valuation at Morgan Stanley
12/15/20 Morgan Stanley
Intuitive Surgical downgraded to Equal Weight from Overweight at Morgan Stanley
11/24/20 Raymond James
Intuitive Surgical not surprised by J&J robot features, says Raymond James
ISRG Intuitive Surgical
$799.43 /

-0.18 (-0.02%)

ISRG Intuitive Surgical
$799.43 /

-0.18 (-0.02%)

ISRG Intuitive Surgical
$799.43 /

-0.18 (-0.02%)

Recommendations
Intuitive Surgical price target raised to $730 from $680 at Piper Sandler » 05:02
01/22/21
01/22
05:02
01/22/21
05:02
ISRG

Intuitive Surgical

$799.43 /

-0.18 (-0.02%)

Piper Sandler analyst…

Piper Sandler analyst Adam Maeder raised the firm's price target on Intuitive Surgical to $730 from $680 and keeps a Neutral rating on the shares following the company's "solid" Q4 results. model. There were no real surprises on the earnings call given the pre-announcement and the company elected not to provide any financial guidance due to the ongoing pandemic, Maeder tells investors in a research note.

ShowHide Related Items >><<
ISRG Intuitive Surgical
$799.43 /

-0.18 (-0.02%)

ISRG Intuitive Surgical
$799.43 /

-0.18 (-0.02%)

12/15/20 Morgan Stanley
Intuitive Surgical downgraded to Equal Weight on valuation at Morgan Stanley
12/15/20 Morgan Stanley
Intuitive Surgical downgraded to Equal Weight from Overweight at Morgan Stanley
11/24/20 Raymond James
Intuitive Surgical not surprised by J&J robot features, says Raymond James
10/16/20 JPMorgan
Intuitive Surgical price target raised to $785 from $765 at JPMorgan
ISRG Intuitive Surgical
$799.43 /

-0.18 (-0.02%)

ISRG Intuitive Surgical
$799.43 /

-0.18 (-0.02%)

ISRG Intuitive Surgical
$799.43 /

-0.18 (-0.02%)

Thursday
On The Fly
Fly Intel: After-Hours Movers » 18:35
01/21/21
01/21
18:35
01/21/21
18:35
SIVB

SVB Financial

$455.02 /

-7.49 (-1.62%)

, WAL

Western Alliance

$69.40 /

-1.92 (-2.69%)

, INDB

Independent Bank

$78.68 /

-1.39 (-1.74%)

, OZK

Bank OZK

$34.03 /

-0.59 (-1.70%)

, FLDM

Fluidigm

$6.17 /

+0.31 (+5.29%)

, MNOV

MediciNova

$5.78 /

+0.09 (+1.58%)

, SWIR

Sierra Wireless

$18.41 /

+0.02 (+0.11%)

, ALDX

Aldeyra

$11.77 /

-0.48 (-3.92%)

, AMRN

Amarin

$6.31 /

+0.11 (+1.78%)

, IBM

IBM

$131.80 /

+1.72 (+1.32%)

, STX

Seagate

$63.00 /

+1.57 (+2.56%)

, PPG

PPG

$143.94 /

-0.635 (-0.44%)

, ISRG

Intuitive Surgical

$799.43 /

-0.18 (-0.02%)

, CSX

CSX

$91.61 /

-1.6101 (-1.73%)

, PGEN

Precigen

$9.18 /

-0.22 (-2.34%)

, ACB

Aurora Cannabis

$11.17 /

-0.39 (-3.37%)

, F

Ford

$11.53 /

+0.665 (+6.12%)

Check out this evening's…

ShowHide Related Items >><<
SWIR Sierra Wireless
$18.41 /

+0.02 (+0.11%)

STX Seagate
$63.00 /

+1.57 (+2.56%)

SIVB SVB Financial
$455.02 /

-7.49 (-1.62%)

PPG PPG
$143.94 /

-0.635 (-0.44%)

PGEN Precigen
$9.18 /

-0.22 (-2.34%)

OZK Bank OZK
$34.03 /

-0.59 (-1.70%)

MNOV MediciNova
$5.78 /

+0.09 (+1.58%)

ISRG Intuitive Surgical
$799.43 /

-0.18 (-0.02%)

IBM IBM
$131.80 /

+1.72 (+1.32%)

FLDM Fluidigm
$6.17 /

+0.31 (+5.29%)

F Ford
$11.53 /

+0.665 (+6.12%)

CSX CSX
$91.61 /

-1.6101 (-1.73%)

AMRN Amarin
$6.31 /

+0.11 (+1.78%)

ALDX Aldeyra
$11.77 /

-0.48 (-3.92%)

ACB Aurora Cannabis
$11.17 /

-0.39 (-3.37%)

SIVB SVB Financial
$455.02 /

-7.49 (-1.62%)

01/08/21 Oppenheimer
Oppenheimer calls SVB Financial acquisition of Boston Private a 'good move'
01/05/21 DA Davidson
SVB Financial price target raised to $400 from $365 at DA Davidson
01/05/21 Raymond James
SVB Financial price target raised to $440 from $325 at Raymond James
01/05/21 RBC Capital
SVB Financial price target raised to $437 from $320 at RBC Capital
WAL Western Alliance
$69.40 /

-1.92 (-2.69%)

01/08/21 UBS
Western Alliance upgraded to Buy from Neutral at UBS
01/04/21 Stephens
Brinker, LiveRamp and Vonage among 2021 best ideas at Stephens
12/15/20 Truist
Truist raises price targets on select regional banks
11/04/20 Stephens
Western Alliance resumed with an Overweight at Stephens
INDB Independent Bank
$78.68 /

-1.39 (-1.74%)

12/17/20 Seaport Global
Seaport Global rolls out coverage of Regional and Community Banks with 4 Buys
12/17/20 Seaport Global
Independent Bank initiated with a Neutral at Seaport Global
10/26/20 Compass Point
Independent Bank upgraded to Buy from Neutral at Compass Point
06/24/20 Piper Sandler
Independent Bank downgraded to Neutral from Overweight at Piper Sandler
OZK Bank OZK
$34.03 /

-0.59 (-1.70%)

06/17/20 Raymond James
Bank OZK upgraded to Outperform from Market Perform at Raymond James
06/17/20 Citi
Bank OZK downgraded to Neutral from Buy at Citi
06/17/20 Raymond James
Bank OZK upgraded to Outperform from Market Perform at Raymond James
04/28/20 Truist
Bank OZK price target raised to $22 from $19 at SunTrust
FLDM Fluidigm
$6.17 /

+0.31 (+5.29%)

12/17/20 BTIG
Illumina upgraded to Buy from Neutral at BTIG
11/09/20 Piper Sandler
Buy companies with COVID-19 tests on today's selloff, says Piper Sandler
10/19/20 Piper Sandler
Fluidigm test pact in Texas 'another validation,' says Piper Sandler
09/29/20 Piper Sandler
Piper Sandler would be buyers of Fluidigm given recent pullback
MNOV MediciNova
$5.78 /

+0.09 (+1.58%)

SWIR Sierra Wireless
$18.41 /

+0.02 (+0.11%)

01/14/21
Fly Intel: Top five analyst initiations
01/14/21 B. Riley Securities
Sierra Wireless initiated with a Buy at B. Riley Securities
11/25/20 Colliers
Sierra Wireless initiated with a Buy at Colliers
02/14/20 Roth Capital
Roth Capital sees upside in Sierra Wireless after 2020 transition year
ALDX Aldeyra
$11.77 /

-0.48 (-3.92%)

01/08/21 Jefferies
Aldeyra could double if topline of TRANQUILITY study positive, says Jefferies
01/08/21 Citi
Aldeyra shares have 'plenty of upside' despite 26% rally, says Citi
01/07/21 Alliance Global Partners
Aldeyra in an 'enviable position' after Phase 3 Tranquility data, says AGP
12/16/20 Berenberg
Berenberg starts Aldeyra with Buy, sees near-term catalysts
AMRN Amarin
$6.31 /

+0.11 (+1.78%)

01/08/21 Piper Sandler
Piper sees 're-birth' for Amarin shares in 2021, keeps $19 price target
12/28/20 Cantor Fitzgerald
Vascepa showing positive year-over-year trends, says Cantor Fitzgerald
12/23/20 Goldman Sachs
Amarin price target lowered to $6 from $8 at Goldman Sachs
12/14/20 Piper Sandler
Amarin's Vascepa showed 'encouraging results' in Covid patients, says Piper
IBM IBM
$131.80 /

+1.72 (+1.32%)

10/20/20 Morgan Stanley
Morgan Stanley continues to view IBM as 'a 2022 stock'
10/20/20 Citi
IBM is 'getting even more complex,' says Citi
10/20/20 BMO Capital
IBM price target lowered to $138 from $140 at BMO Capital
10/09/20 Morgan Stanley
IBM price target raised to $140 from $128 at Morgan Stanley
STX Seagate
$63.00 /

+1.57 (+2.56%)

01/21/21 Barclays
Seagate price target raised to $60 from $41 at Barclays
01/20/21 Wedbush
Seagate price target raised to $56 from $47 at Wedbush
01/19/21 Northland
Seagate price target raised to $72 from $65 at Northland
01/19/21 Loop Capital
Seagate price target raised to $70 from $60 at Loop Capital
PPG PPG
$143.94 /

-0.635 (-0.44%)

01/20/21 Citi
Citi adds PPG to US Focus List, removes FMC
01/14/21 Berenberg
PPG upgraded to Buy with $165 price target at Berenberg
01/14/21 Berenberg
PPG upgraded to Buy from Hold at Berenberg
12/01/20 Deutsche Bank
PPG price target raised to $165 from $155 at Deutsche Bank
ISRG Intuitive Surgical
$799.43 /

-0.18 (-0.02%)

12/15/20 Morgan Stanley
Intuitive Surgical downgraded to Equal Weight on valuation at Morgan Stanley
12/15/20 Morgan Stanley
Intuitive Surgical downgraded to Equal Weight from Overweight at Morgan Stanley
11/24/20 Raymond James
Intuitive Surgical not surprised by J&J robot features, says Raymond James
10/16/20 JPMorgan
Intuitive Surgical price target raised to $785 from $765 at JPMorgan
CSX CSX
$91.61 /

-1.6101 (-1.73%)

01/20/21 Susquehanna
Railroad recovery expected to continue in 2021, says Susquehanna
01/11/21 Citi
CSX price target raised to $105 from $87 at Citi
12/10/20 Morgan Stanley
Morgan Stanley downgrades CSX to Underweight with bar raised too high
12/10/20 Morgan Stanley
CSX downgraded to Underweight from Equal Weight at Morgan Stanley
PGEN Precigen
$9.18 /

-0.22 (-2.34%)

12/16/20 H.C. Wainwright
Precigen price target raised to $10 from $8 at H.C. Wainwright
05/08/20
Fly Intel: Top analyst initiations
05/08/20 H.C. Wainwright
Precigen initiated with a Buy at H.C. Wainwright
ACB Aurora Cannabis
$11.17 /

-0.39 (-3.37%)

01/06/21 BMO Capital
Federal cannabis reform in U.S. likely to take time, says BMO Capital
12/17/20 BMO Capital
Aurora Cannabis downgraded to Underperform from Market Perform at BMO Capital
12/04/20 Alliance Global Partners
Alliance Global sees low odds of MORE Act passing this congressional session
12/02/20 Alliance Global Partners
Alliance Global Partners sees UN cannabis reclassification helping legalization
F Ford
$11.53 /

+0.665 (+6.12%)

01/20/21 Deutsche Bank
Ford price target raised to $11 from $9 at Deutsche Bank
01/20/21 Deutsche Bank
Ford named 'Catalyst Call: Buy Idea' at Deutsche Bank
01/05/21 Benchmark
GM, Roku, Marcus among Benchmark's Best Ideas for first half of 2021
12/23/20 Morgan Stanley
Apple's potential EV entry represents 'new Tesla bear case,' says Morgan Stanley
WAL Western Alliance
$69.40 /

-1.92 (-2.69%)

SWIR Sierra Wireless
$18.41 /

+0.02 (+0.11%)

STX Seagate
$63.00 /

+1.57 (+2.56%)

SIVB SVB Financial
$455.02 /

-7.49 (-1.62%)

PPG PPG
$143.94 /

-0.635 (-0.44%)

PGEN Precigen
$9.18 /

-0.22 (-2.34%)

OZK Bank OZK
$34.03 /

-0.59 (-1.70%)

ISRG Intuitive Surgical
$799.43 /

-0.18 (-0.02%)

INDB Independent Bank
$78.68 /

-1.39 (-1.74%)

IBM IBM
$131.80 /

+1.72 (+1.32%)

FLDM Fluidigm
$6.17 /

+0.31 (+5.29%)

F Ford
$11.53 /

+0.665 (+6.12%)

CSX CSX
$91.61 /

-1.6101 (-1.73%)

AMRN Amarin
$6.31 /

+0.11 (+1.78%)

ALDX Aldeyra
$11.77 /

-0.48 (-3.92%)

ACB Aurora Cannabis
$11.17 /

-0.39 (-3.37%)

  • 22
    Jan
  • 22
    Jan
  • 14
    Jan
  • 11
    Nov
IBM IBM
$131.80 /

+1.72 (+1.32%)

FLDM Fluidigm
$6.17 /

+0.31 (+5.29%)

F Ford
$11.53 /

+0.665 (+6.12%)

AMRN Amarin
$6.31 /

+0.11 (+1.78%)

ACB Aurora Cannabis
$11.17 /

-0.39 (-3.37%)

STX Seagate
$63.00 /

+1.57 (+2.56%)

SIVB SVB Financial
$455.02 /

-7.49 (-1.62%)

PPG PPG
$143.94 /

-0.635 (-0.44%)

MNOV MediciNova
$5.78 /

+0.09 (+1.58%)

ISRG Intuitive Surgical
$799.43 /

-0.18 (-0.02%)

IBM IBM
$131.80 /

+1.72 (+1.32%)

FLDM Fluidigm
$6.17 /

+0.31 (+5.29%)

F Ford
$11.53 /

+0.665 (+6.12%)

CSX CSX
$91.61 /

-1.6101 (-1.73%)

AMRN Amarin
$6.31 /

+0.11 (+1.78%)

ACB Aurora Cannabis
$11.17 /

-0.39 (-3.37%)

STX Seagate
$63.00 /

+1.57 (+2.56%)

PPG PPG
$143.94 /

-0.635 (-0.44%)

PGEN Precigen
$9.18 /

-0.22 (-2.34%)

MNOV MediciNova
$5.78 /

+0.09 (+1.58%)

ISRG Intuitive Surgical
$799.43 /

-0.18 (-0.02%)

IBM IBM
$131.80 /

+1.72 (+1.32%)

FLDM Fluidigm
$6.17 /

+0.31 (+5.29%)

F Ford
$11.53 /

+0.665 (+6.12%)

CSX CSX
$91.61 /

-1.6101 (-1.73%)

AMRN Amarin
$6.31 /

+0.11 (+1.78%)

ACB Aurora Cannabis
$11.17 /

-0.39 (-3.37%)

Hot Stocks
Intuitive Surgical says overall procedure growth was 6% in Q4 » 17:01
01/21/21
01/21
17:01
01/21/21
17:01
ISRG

Intuitive Surgical

$799.43 /

-0.18 (-0.02%)

Says delays in diagnostic…

Says delays in diagnostic pipelines due to COVID-19 will likely take quarters to resolve. Says delays will also pressure new system installs. Says obstacles make predictions for next couple of quarters difficult. Says resurgence of Covid in parts of Europe had a large impact on procedures. Says resurgence also impacted U.S. market. Says half of the systems placed in Q4 involved trade-ins. Says Q4 average selling prices decreased. Says procedure growth accelerated in China. Comments taken from Q4 earnings conference call.

ShowHide Related Items >><<
ISRG Intuitive Surgical
$799.43 /

-0.18 (-0.02%)

ISRG Intuitive Surgical
$799.43 /

-0.18 (-0.02%)

12/15/20 Morgan Stanley
Intuitive Surgical downgraded to Equal Weight on valuation at Morgan Stanley
12/15/20 Morgan Stanley
Intuitive Surgical downgraded to Equal Weight from Overweight at Morgan Stanley
11/24/20 Raymond James
Intuitive Surgical not surprised by J&J robot features, says Raymond James
10/16/20 JPMorgan
Intuitive Surgical price target raised to $785 from $765 at JPMorgan
ISRG Intuitive Surgical
$799.43 /

-0.18 (-0.02%)

ISRG Intuitive Surgical
$799.43 /

-0.18 (-0.02%)

ISRG Intuitive Surgical
$799.43 /

-0.18 (-0.02%)

Hot Stocks
ViiV Healthcare announces FDA approval of Cabenuva » 16:46
01/21/21
01/21
16:46
01/21/21
16:46
GSK

GlaxoSmithKline

$37.79 /

-0.23 (-0.60%)

, PFE

Pfizer

$36.49 /

+0.01 (+0.03%)

, JNJ

Johnson & Johnson

$161.69 /

-0.71 (-0.44%)

ViiV Healthcare, the…

ViiV Healthcare, the global specialist HIV company majority owned by GlaxoSmithKline (GSK), with Pfizer (PFE) and Shionogi Limited as shareholders, announced that the U.S. FDA approved Cabenuva, the first and only complete long-acting regimen for the treatment of HIV-1 infection in adults. Cabenuva is provided as a co-pack with two injectable medicines, ViiV Healthcare's cabotegravir and Janssen's (JNJ) rilpivirine, dosed once monthly, as an option to replace the current antiretroviral regimen in those who are virologically suppressed on a stable regimen, with no history of treatment failure, and with no known or suspected resistance to either cabotegravir or rilpivirine. Prior to initiating treatment of Cabenuva, oral dosing of cabotegravir and rilpivirine should be administered for approximately one month to assess the tolerability of each therapy.

ShowHide Related Items >><<
PFE Pfizer
$36.49 /

+0.01 (+0.03%)

JNJ Johnson & Johnson
$161.69 /

-0.71 (-0.44%)

GSK GlaxoSmithKline
$37.79 /

-0.23 (-0.60%)

GSK GlaxoSmithKline
$37.79 /

-0.23 (-0.60%)

01/20/21 UBS
GlaxoSmithKline price target raised to 1,450 GBp from 1,440 GBp at UBS
01/20/21
Fly Intel: Top five analyst downgrades
01/20/21 Credit Suisse
GlaxoSmithKline downgraded to Underperform from Neutral at Credit Suisse
01/20/21 Credit Suisse
GlaxoSmithKline downgraded to Underperform from Neutral at Credit Suisse
PFE Pfizer
$36.49 /

+0.01 (+0.03%)

01/14/21 Morgan Stanley
80%+ efficacy from J&J vaccine would be 'compelling,' says Morgan Stanley
01/14/21 Oppenheimer
Essa Pharma price target raised to $20 from $9 at Oppenheimer
01/05/21 Argus
Viatris initiated with a Hold at Argus
12/31/20 Ladenburg
UK study supports potential of Arcturus COVID vaccine candidate, says Ladenburg
JNJ Johnson & Johnson
$161.69 /

-0.71 (-0.44%)

01/15/21 B. Riley Securities
Arcturus Therapeutics downgraded to Neutral from Buy at B. Riley Securities
12/29/20 Piper Sandler
Piper still believes in Arcturus vaccine after 'underwhelming' immunogenicity
PFE Pfizer
$36.49 /

+0.01 (+0.03%)

JNJ Johnson & Johnson
$161.69 /

-0.71 (-0.44%)

GSK GlaxoSmithKline
$37.79 /

-0.23 (-0.60%)

PFE Pfizer
$36.49 /

+0.01 (+0.03%)

JNJ Johnson & Johnson
$161.69 /

-0.71 (-0.44%)

GSK GlaxoSmithKline
$37.79 /

-0.23 (-0.60%)

PFE Pfizer
$36.49 /

+0.01 (+0.03%)

JNJ Johnson & Johnson
$161.69 /

-0.71 (-0.44%)

GSK GlaxoSmithKline
$37.79 /

-0.23 (-0.60%)

PFE Pfizer
$36.49 /

+0.01 (+0.03%)

JNJ Johnson & Johnson
$161.69 /

-0.71 (-0.44%)

GSK GlaxoSmithKline
$37.79 /

-0.23 (-0.60%)

Earnings
Intuitive Surgical reports Q4 EPS $3.58, consensus $3.12 » 16:09
01/21/21
01/21
16:09
01/21/21
16:09
ISRG

Intuitive Surgical

$796.66 /

-2.95 (-0.37%)

Reports Q4 revenue…

Reports Q4 revenue $1.33B, consensus $1.24B. Worldwide da Vinci procedures increased approximately 6% compared with Q4 of 2019, reflecting continued disruption caused by the COVID-19 pandemic. The company shipped 326 da Vinci Surgical Systems, a decrease of 3% compared with 336 in Q4 of 2019. The company said, "During 2020, da Vinci procedure volumes and system placements were significantly impacted by the COVID-19 pandemic, as healthcare systems around the world diverted resources to respond to COVID-19. The impact of the COVID-19 pandemic on the Company's business has, and continues to, differ by geography and region. In the U.S., for example, while da Vinci procedures had recovered a significant portion of the pre-COVID-19 levels, the resurgence of COVID-19, particularly later in the fourth quarter and into January, has had, and will likely continue to have, an adverse impact on the Company's procedure volumes. Due to the continued uncertainty around the scope and duration of the pandemic globally, we cannot, at this time, reliably estimate the future impact on our operations and financial results."

ShowHide Related Items >><<
ISRG Intuitive Surgical
$796.66 /

-2.95 (-0.37%)

ISRG Intuitive Surgical
$796.66 /

-2.95 (-0.37%)

12/15/20 Morgan Stanley
Intuitive Surgical downgraded to Equal Weight on valuation at Morgan Stanley
12/15/20 Morgan Stanley
Intuitive Surgical downgraded to Equal Weight from Overweight at Morgan Stanley
11/24/20 Raymond James
Intuitive Surgical not surprised by J&J robot features, says Raymond James
10/16/20 JPMorgan
Intuitive Surgical price target raised to $785 from $765 at JPMorgan
ISRG Intuitive Surgical
$796.66 /

-2.95 (-0.37%)

ISRG Intuitive Surgical
$796.66 /

-2.95 (-0.37%)

ISRG Intuitive Surgical
$796.66 /

-2.95 (-0.37%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.